Aflac (AFL) has drawn fresh attention after adding a long term care rider to its Group Life Term to 120 policy, aligning its product lineup with rising care needs among aging Americans.
See our latest analysis for Aflac.
Despite the new long term care rider and recent governance debates around separating the CEO and chair roles, Aflac’s 30 day share price return of a 5.8% decline and year to date share price return of a 3.5% decline contrast with a much stronger 3 year total shareholder return of 76.1% and 5 year total shareholder return of 132.1%. This suggests longer term momentum has been stronger than the recent pullback.
If you are weighing Aflac’s move into long term care against other themes reshaping markets, it can be useful to see how many companies are building the infrastructure behind AI growth using our 35 AI infrastructure stocks
With Aflac shares down over the past year but still carrying a premium to analyst targets and some intrinsic value estimates, you have to ask: is this a quality insurer on sale, or is the market already pricing in future growth?
Most Popular Narrative: 5.8% Undervalued
Aflac’s most followed narrative pegs fair value at $113, a touch above the last close of $106.41, which frames the current pullback as a modest discount under that view.
Increased adoption of digital underwriting, customer-facing Gen AI, and digital human avatar initiatives in both Japan and the U.S. is expected to lower long-term operational costs and improve customer engagement, with the potential to materially expand net margins through enhanced efficiency and better scalability.
How might a mature insurer justify that valuation gap? The narrative focuses on steady premium growth, firm margins, and the possibility of a higher future earnings multiple. The specific combination of growth, profitability, and discount rate assumptions is where the story becomes more detailed.
Result: Fair Value of $113 (UNDERVALUED)
Have a read of the narrative in full and understand what's behind the forecasts.
However, that optimistic outlook could be tested if Japan premium headwinds and higher technology spending persist, or if currency and investment volatility continue to put pressure on earnings and margins.
Find out about the key risks to this Aflac narrative.
Another View: Premium Price Tag
While the narrative suggests Aflac is 5.8% undervalued on a fair value of $113, the current P/E of 15x sits above both the US Insurance industry at 10.9x and peers at 13.8x, and above a fair ratio of 12.3x. This raises a clear question: is this really a discount, or a quality premium that could compress?
See what the numbers say about this price — find out in our valuation breakdown.
Next Steps
With mixed signals on valuation and sentiment, do you feel the current pricing accurately reflects Aflac’s balance of risks and rewards? Act while the data is fresh and review the 2 key rewards and 1 important warning sign
Looking for more investment ideas?
If Aflac has you thinking more broadly about your portfolio, now is the time to scan for other opportunities before the market moves on without you.
- Target potential bargains by checking companies that combine quality and attractive pricing using the 62 high quality undervalued stocks.
- Strengthen your income stream by reviewing companies identified as resilient payers in the 12 dividend fortresses.
- Focus on financial resilience by searching for companies with conservative risk profiles through the 64 resilient stocks with low risk scores.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com